School of Medicine Homepage
Emory University Shield
  • About
    • Our Vision
    • Academic Departments
    • Our Leadership
    • Health Care Partnerships
    • Diversity, Equity, & Inclusion
    • Location
    • Supporting Our People
    • Our Faculty
    • History
    • News
    • Events
    • Contact Us
  • Education
    • Degree and Certificate Programs
    • Academic Departments
    • Residents & Fellows
    • Postdoctoral Training
    • Continuing Medical Education
    • Admissions
    • Cost and Financial Aid
    • Student Resources
  • Research
    • Research Innovation
    • Conducting Research
    • Core Facilities
    • Research Centers
    • Research Training
    • Academic Departments
    • Find a Researcher
    • Research News
  • Clinical Experience
    • Where We Work
    • Caring for a Diverse Population
    • Faculty Clinical Experience
    • Advanced Patient Care
    • Academic Departments
    • Community Learning
  • Giving
  • Directory

Directory section navigation

  • Faculty Profiles

Emory University School of Medicine

  • About
    • Sub link
      Our Vision
    • Sub link
      Academic Departments
    • Sub link
      Our Leadership
    • Sub link
      Health Care Partnerships
    • Sub link
      Diversity, Equity, & Inclusion
    • Sub link
      Location
    • Sub link
      Supporting Our People
    • Sub link
      Our Faculty
    • Sub link
      History
    • Sub link
      News
    • Sub link
      Events
    • Sub link
      Contact Us
  • Education
    • Sub link
      Degree and Certificate Programs
    • Sub link
      Academic Departments
    • Sub link
      Residents & Fellows
    • Sub link
      Postdoctoral Training
    • Sub link
      Continuing Medical Education
    • Sub link
      Admissions
    • Sub link
      Cost and Financial Aid
    • Sub link
      Student Resources
  • Research
    • Sub link
      Research Innovation
    • Sub link
      Conducting Research
    • Sub link
      Core Facilities
    • Sub link
      Research Centers
    • Sub link
      Research Training
    • Sub link
      Academic Departments
    • Sub link
      Find a Researcher
    • Sub link
      Research News
  • Clinical Experience
    • Sub link
      Where We Work
    • Sub link
      Caring for a Diverse Population
    • Sub link
      Faculty Clinical Experience
    • Sub link
      Advanced Patient Care
    • Sub link
      Academic Departments
    • Sub link
      Community Learning
  • Giving
  • Directory
  • Home School of Medicine Home
  • Directory

Profile

Elizabeth Stenger

  • Department of Pediatrics
    Associate Professor
  • elizabeth.stenger@emory.edu
Head shot of Elizabeth Stenger

Academic Appointment

  • Assistant Professor of Pediatrics, Aflac Cancer & Blood Disorders Center, Emory University

Education

Degrees

  • MSCR from Emory University
  • MD from University of Pittsburgh
  • BS from University of Notre Dame

Research

Publications

  • Late effects after allogeneic haematopoietic cell transplantation in children and adolescents with non-malignant disorders: a retrospective cohort study.
    Lancet Child Adolesc Health Volume: 8 Page(s): 740 - 750
    10/01/2024 Authors: Kahn J; Brazauskas R; Bo-Subait S; Buchbinder D; Hamilton BK; Schoemans H; Abraham AA; Agrawal V; Auletta JJ; Badawy SM
  • Long-term quality of life after hematopoietic cell transplant for sickle cell disease in childhood: A STELLAR interim analysis.
    Am J Hematol Volume: 99 Page(s): 2037 - 2040
    10/01/2024 Authors: Arnold SD; Bakshi N; Ross D; Smith C; Sinha C; Veludhandi A; Dutreuil V; Bai S; Meacham LR; Guilcher G
  • Reproductive Health Assessment and Reports of Fertility Counseling in Pediatric and Adolescent Patients with Sickle Cell Disease After Hematopoietic Cell Transplantation.
    Transplant Cell Ther Volume: 30 Page(s): 912.e1 - 912.e13
    09/01/2024 Authors: George SA; Veludhandi A; Xiang Y; Liu K; Stenger E; Arnold SD; Mehta A; Schirmer DA; Spencer JB; Guilcher GMT
  • Real-World Application of Recently Proposed ASTCT/CIBMTR/EBMT/APBMT Consensus Risk Stratification for Transplantation-Associated Thrombotic Microangiopathy in Children.
    Transplant Cell Ther Volume: 30 Page(s): 929.e1 - 929.e6
    09/01/2024 Authors: Schoettler ML; Ofori J; Bryson E; Spencer K; Qayed M; Stenger E; Bidgoli A; Chonat S; Westbrook A; Williams KM
  • Age, GVHD prophylaxis, and timing matter in thrombotic microangiopathy after haematopoietic cell transplantation-Asecondary CIBMTR analysis.
    Br J Haematol Volume: 205 Page(s): 243 - 255
    07/01/2024 Authors: Schoettler ML; Westbrook A; Watkins B; Stenger E; Qayed M; Chonat S; Williams KM
  • D-dimer and sinusoidal obstructive syndrome-novel poor prognostic features of thrombotic microangiopathy in children after hematopoietic cellular therapy in a single institution prospective cohort study.
    Am J Hematol Volume: 99 Page(s): 370 - 379
    03/01/2024 Authors: Schoettler ML; French K; Harris A; Bryson E; Deeb L; Hudson Z; Obordo J; Chandrakasan S; Parikh S; Watkins B
  • Life after sickle cell disease, is it really uhuru?
    Lancet Haematol Volume: 10 Page(s): e946 - e949
    12/01/2023 Authors: Pecker LH; Akinsete AM; Carroll CP; Lanzkron S; Kuo KHM; Hulbert M; Stenger E; Darbari DS
  • Short-Course Empiric Antibiotics in Children Undergoing Allogeneic Hematopoietic Cell Transplantation.
    Transplant Cell Ther Volume: 29 Page(s): 778.e1 - 778.e6
    12/01/2023 Authors: Patel PA; Teherani MF; Xiang Y; Bernardo V; Chandrakasan S; Goggin KP; Haight A; Horwitz E; Liang WH; Parikh SH
  • Severe refractory hemorrhagic cystitis after hematopoietic cell transplantation responds to recombinant human keratinocyte growth factor-Case report and review of the literature.
    Pediatr Blood Cancer Volume: 70 Page(s): e30606
    10/01/2023 Authors: Hughes C; Harris A; Watkins B; Qayed M; Parikh S; Horwitz E; Stenger E; Williams KM; Schoettler ML
  • Female Reproductive Health Outcomes after Hematopoietic Cell Transplantation for Sickle Cell Disease: Is Reduced Intensity Better Than Myeloablative Conditioning?
    Transplant Cell Ther Volume: 29 Page(s): 531.e1 - 531.e4
    08/01/2023 Authors: Meacham LR; George S; Veludhandi A; Pruett MC; Haight AE; Arnold SD; Elchuri S; Stenger E; Krishnamurti L
  • Alemtuzumab and CXCL9 levels predict likelihood of sustained engraftment after reduced-intensity conditioning HCT.
    Blood Adv Volume: 7 Page(s): 3725 - 3734
    07/25/2023 Authors: Geerlinks AV; Scull B; Krupski C; Fleischmann R; Pulsipher MA; Eapen M; Connelly JA; Bollard CM; Pai S-Y; Duncan CN
  • FOLLOW-UP OF MIXED CHIMERISM IN HEMATOPOIETIC CELL TRANSPLANTS (HCT) FOR SICKLE CELL DISEASE (SCD)
    Volume: 70 Page(s): S190 - S191
    06/01/2023 Authors: Dalal S; Suresh T; Yelamali A; Bhatia M; Haight A; Khandelwal P; Khoury R; Lafay Q; Mandava M; Nickel R
  • IMPACT OF TRANSPLANT ASSOCIATED THROMBOTIC MICROANGIOPATHY AND ACUTE GRAFT VERSUS HOST DISEASE ON SURVIVAL IN CHILDREN AFTER ALLOGENEIC HEMATOPOIETIC CELLULAR TRANSPLANTATION
    Volume: 70 Page(s): S217 - S217
    06/01/2023 Authors: Schoettler M; Harris A; Bryson E; Deeb L; Watkins B; Haight A; Parikh S; Chandrakasan S; Stenger E; Liang W
  • Abatacept GVHD prophylaxis in unrelated hematopoietic cell transplantation for pediatric bone marrow failure.
    Blood Adv Volume: 7 Page(s): 2196 - 2205
    05/23/2023 Authors: Stenger EO; Watkins B; Rogowski K; Chiang K-Y; Haight A; Leung K; Qayed M; Raghunandan S; Suessmuth Y; Kean L
  • Sickle cell disease is a risk factor for transplant-associated thrombotic microangiopathy in children.
    Blood Adv Volume: 7 Page(s): 1784 - 1795
    05/09/2023 Authors: Schoettler M; Stenger E; Spencer K; Lutterman D; Rumbika S; Jones J; Haight A; Parikh S; Qayed M; Watkins B
  • Long-Term Organ Function After HCT for SCD: A Report From the Sickle Cell Transplant Advocacy and Research Alliance.
    Transplant Cell Ther Volume: 29 Page(s): 47.e1 - 47.e10
    01/01/2023 Authors: Stenger E; Xiang Y; Wetzel M; Gillespie S; Chellapandian D; Shah R; Arnold SD; Bhatia M; Chaudhury S; Eckrich MJ
  • Sickle Cell Transplantation Evaluation of Long-term and Late Effects Registry (STELLAR) to Compare Long-term Outcomes After Hematopoietic Cell Transplantation to Those in Siblings Without Sickle Cell Disease and in Nontransplanted Individuals With Sickle Cell Disease: Design and Feasibility Study.
    JMIR Res Protoc Volume: 11 Page(s): e36780
    07/06/2022 Authors: Krishnamurti L; Arnold SD; Haight A; Abraham A; Guilcher GM; John T; Bakshi N; Shenoy S; Syrjala K; Martin PL
  • REDUCING DURATION OF EMPIRIC ANTIBIOTICS IN CHILDREN UNDERGOING STEM CELL TRANSPLANTATION
    Volume: 69
    06/01/2022 Authors: Patel P; Teherani M; Xiang Y; Bernardo V; Chandrakasan S; Goggin K; Haight A; Horwitz E; Liang W; Parikh S
  • Comparison of hematopoietic cell transplant conditioning regimens for hemophagocytic lymphohistiocytosis disorders.
    J Allergy Clin Immunol Volume: 149 Page(s): 1097 - 1104.e2
    03/01/2022 Authors: Marsh RA; Hebert K; Kim S; Dvorak CC; Aquino VM; Baker KS; Chellapandian D; Dvila Saldaa B; Duncan CN; Eckrich MJ
  • High risk of relapsed disease in patients with NK/T-cell chronic active Epstein-Barr virus disease outside of Asia.
    Blood Adv Volume: 6 Page(s): 452 - 459
    01/25/2022 Authors: Dvila Saldaa BJ; John T; Bonifant C; Buchbinder D; Chandra S; Chandrakasan S; Chang W; Chen L; Elfassy HL; Geerlinks AV
  • Safety of autologous freshly expanded mesenchymal stromal cells for the treatment of graft-versus-host disease.
    Front Immunol Volume: 13 Page(s): 959658
    01/01/2022 Authors: Stenger E; Giver CR; Langston A; Kota D; Das PK; Chinnadurai R; Galipeau J; Waller EK; Qayed M
  • HSC engraftment in SCD: a MiSCing piece of the puzzle?
    Blood Volume: 138 Page(s): 2451 - 2452
    12/16/2021 Authors: Stenger E
  • EVALUATION OF BUFFERS TO OPTIMIZE THAWING OF CRYOPRESERVED PRODUCTS FOR REGULATORY T CELL ISOLATION
    Volume: 23 Page(s): S163 - S164
    05/01/2021 Authors: Baron KJ; Stenger E; Chen X; Long N; Stanczak H; Ullman M; Szabolcs P
  • Conditioning Regimens and Outcomes after Allogeneic Hematopoietic Cell Transplant for Hyperinflammatory Inborn Errors of Immunity
    Volume: 136
    11/05/2020 Authors: Marsh RA; Kim S; Hebert K; Dvorak CC; Aquino V; Baker KSS; Chellapandian D; Davila B; Duncan C; Eckrich MJ
  • Correction: Chronic Granulomatous Disease-Associated IBD Resolves and Does Not Adversely Impact Survival Following Allogeneic HCT.
    J Clin Immunol Volume: 40 Page(s): 1211 - 1213
    11/01/2020 Authors: Marsh RA; Leiding JW; Logan BR; Griffith LM; Arnold DE; Haddad E; Falcone EL; Yin Z; Patel K; Arbuckle E
  • Reduced-intensity single-unit unrelated cord blood transplant with optional immune boost for nonmalignant disorders (vol 4, pg 3041, 2020)
    BLOOD ADVANCES Volume: 4 Page(s): 3508 - 3508
    08/11/2020 Authors: Lugt MTV; Chen X; Escolar ML; Carella BA; Barnum JL; Windreich RM; Hill MJ; Poe M; Marsh RA; Stanczak H
  • Reduced-intensity single-unit unrelated cord blood transplant with optional immune boost for nonmalignant disorders.
    Blood Adv Volume: 4 Page(s): 3041 - 3052
    07/14/2020 Authors: Vander Lugt MT; Chen X; Escolar ML; Carella BA; Barnum JL; Windreich RM; Hill MJ; Poe M; Marsh RA; Stanczak H
  • How I treat sickle cell disease with hematopoietic cell transplantation.
    Blood Volume: 134 Page(s): 2249 - 2260
    12/19/2019 Authors: Stenger EO; Shenoy S; Krishnamurti L
  • Hematopoietic Stem Cell Transplantation to Treat Leukodystrophies: Clinical Practice Guidelines from the Hunter's Hope Leukodystrophy Care Network.
    Biol Blood Marrow Transplant Volume: 25 Page(s): e363 - e374
    12/01/2019 Authors: Page KM; Stenger EO; Connelly JA; Shyr D; West T; Wood S; Case L; Kester M; Shim S; Hammond L
  • Chronic Granulomatous Disease-Associated IBD Resolves and Does Not Adversely Impact Survival Following Allogeneic HCT.
    J Clin Immunol Volume: 39 Page(s): 653 - 667
    10/01/2019 Authors: Marsh RA; Leiding JW; Logan BR; Griffith LM; Arnold DE; Haddad E; Falcone EL; Yin Z; Patel K; Arbuckle E
  • Sirolimus-associated pericardial effusion with cardiac tamponade and interstitial pneumonitis in a hematopoietic stem cell transplant recipient.
    Pediatr Transplant Volume: 23 Page(s): e13425
    06/01/2019 Authors: Joo SJ; Yildirim I; Stenger EO; Anderson EJ
  • Application of Parafilm As a Physical Barrier on CVC Connections Is Feasible and May Reduce Clabsi Among Pediatric HCT Patients
    Volume: 25
    03/01/2019 Authors: Stenger EO; Newton JG; Leong T; Kendrick L; McManus L; Rooke C; Krishnamurti L
  • Reduced-intensity conditioning for hematopoietic cell transplant for HLH and primary immune deficiencies.
    Blood Volume: 132 Page(s): 1438 - 1451
    09/27/2018 Authors: Allen CE; Marsh R; Dawson P; Bollard CM; Shenoy S; Roehrs P; Hanna R; Burroughs L; Kean L; Talano J-A
  • LONGTERM BONE HEALTH FOLLOWING CURATIVE HEMATOPOIETIC CELL TRANSPLANTATION FOR SICKLE CELL DISEASE
    Volume: 65
    06/01/2018 Authors: Khemani K; Meacham L; Krishnamurti L; Stenger EO
  • Recent outcome of hematopoietic cell transplantation for Wiskott-Aldrich syndrome is excellent in all donor types: A Primary Immune Deficiency Treatment Consortium (PIDTC) Study
    Volume: 38 Page(s): 399 - 400
    04/01/2018 Authors: Pai S-Y; Brazauskas R; Bleesing J; Dvorak CC; Kletzel M; Petrovic A; Prockop SE; Quinones R; Goldman FD; Quigg TC
  • Resolution of CGD Related Colitis after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Chronic Granulomatous Disease-Early Results From the 6903 Study of the Primary Immune Deficiency Treatment Consortium (PIDTC)
    Volume: 24 Page(s): S53 - S54
    03/01/2018 Authors: Leiding JW; Logan BR; Yin Z; Arbuckle E; Bleesing JJ; Sullivan KE; Heimall J; Burroughs L; Skoda-Smith S; Chandrakasan S
  • Immune reconstitution and survival of 100 SCID patients post-hematopoietic cell transplant: a PIDTC natural history study.
    Blood Volume: 130 Page(s): 2718 - 2727
    12/21/2017 Authors: Heimall J; Logan BR; Cowan MJ; Notarangelo LD; Griffith LM; Puck JM; Kohn DB; Pulsipher MA; Parikh S; Martinez C
  • Similar Event-Free Survival but Higher Incidence of Mixed T Cell Chimerism after Hematopoietic Cell Transplantation for Sickle Cell Disease Using Rabbit Versus Horse ATG: a Study from the Sickle Transplant Alliance for Research (STAR)
    Volume: 130
    12/07/2017 Authors: Abraham A; Stenger E; Travers CD; Nickel R; Rangarajan HG; Krajewski J; Chaudhury S; Kasow KA; Quigg TC; Ngwube AI
  • Increased Proportion of Sickle Cell Disease Patients Develop Cardiovascular Disease Risk Factors Following Successful Hematopoietic Cell Transplantation
    Volume: 130
    12/07/2017 Authors: Stenger E; Khemani K; Ross D; Meacham L; McCracken C; Haight A; Krishnamurti L
  • INTACT PHENOTYPE AND FUNCTIONALITY OF BONE MARROW DERIVED MESENCHYMAL STROMAL CELLS FROM INDIVIDUALS WITH SICKLE CELL DISEASE
    Volume: 19 Page(s): S45 - S47
    05/01/2017 Authors: Stenger E; Chinnadurai R; Yuan S; Garcia M; Arafat D; Gibson G; Krishnamurti L; Galipeau J
  • Bone Marrow-Derived Mesenchymal Stromal Cells from Patients with Sickle Cell Disease Display Intact Functionality.
    Biol Blood Marrow Transplant Volume: 23 Page(s): 736 - 745
    05/01/2017 Authors: Stenger EO; Chinnadurai R; Yuan S; Garcia M; Arafat D; Gibson G; Krishnamurti L; Galipeau J
  • CMV Viremia and African-American Ethnicity Are Risk Factors for Post-Engraftment Blood Stream Infections in Pediatric Allogeneic Blood and Marrow Transplantation
    Volume: 128
    12/02/2016 Authors: Sano H; Hilinski J; Applegate K; Camacho-Gonzalez A; Chandrakasan S; Chiang K-Y; Haight A; Krishnamurti L; Stenger E; Qayed M
  • Bone Marrow Derived Mesenchymal Stromal Cells from Patients with Sickle Cell Disease Display Normal Phenotype and Immunomodulatory Capacity
    Volume: 22 Page(s): S148 - S149
    03/01/2016 Authors: Stenger E; Chinnadurai R; Yuan S; Garcia M; Krishnamurti L; Copland I; Galipeau J
  • Mesenchymal stromal cells to modulate immune reconstitution early post-hematopoietic cell transplantation.
    BMC Immunol Volume: 16 Page(s): 74
    12/16/2015 Authors: Stenger EO; Krishnamurti L; Galipeau J
  • Use of Alefacept for Preconditioning in Multiply Transfused Pediatric Patients with Nonmalignant Diseases.
    Biol Blood Marrow Transplant Volume: 21 Page(s): 1845 - 1852
    10/01/2015 Authors: Stenger EO; Chiang K-Y; Haight A; Qayed M; Kean L; Horan J
  • Immune Tolerance Strategies in Siblings with Infantile Pompe Disease-Advantages for a Preemptive Approach to High-Sustained Antibody Titers.
    Mol Genet Metab Rep Volume: 4 Page(s): 30 - 34
    09/01/2015 Authors: Stenger EO; Kazi Z; Lisi E; Gambello MJ; Kishnani P
  • AUTOLOGOUS MESENCHYMAL STROMAL CELLS TO SUPPORT ALLOGENEIC HEMATOPOIETIC STEM CELL ENGRAFTMENT IN SICKLE CELL DISEASE
    Volume: 17 Page(s): S46 - S46
    06/01/2015 Authors: Stenger E; Yuan S; Garcia M; Copland IB; Galipeau J
  • Discordant clinical responses in CRIM-positive IPD siblings demonstrate need for prophylactic ITI in the naive setting
    Volume: 114 Page(s): S22 - S22
    02/01/2015 Authors: Sheets KB; Kazi Z; DeArmey S; Lisi E; Stenger E; Kishnani PS
  • IL-12hi Rapamycin-Conditioned Dendritic Cells Mediate IFN-gamma-Dependent and Fas-Supported Apoptosis of Alloreactive CD4+T Cells and Inhibit Graft-Versus-Host Disease
    Volume: 20 Page(s): S281 - S283
    02/01/2014 Authors: Stenger E; Rosborough B; Mathews L; Ma HH; Mapara MY; Thomson AW; Turnquist H
  • Reduced Intensity Conditioning Regimen Combined with Single Unit Cord Blood Transplantation Is Effective and Safe for Children with Inherited Metabolic Disorders and Combined Immunodeficiency Diseases
    Volume: 20 Page(s): S88 - S89
    02/01/2014 Authors: Vander Lugt M; Chen X; Windreich R; Goyal RK; Stenger E; Escolar M; Szabolcs P
  • IL-12hi rapamycin-conditioned dendritic cells mediate IFN--dependent apoptosis of alloreactive CD4+ T cells in vitro and reduce lethal graft-versus-host disease.
    Biol Blood Marrow Transplant Volume: 20 Page(s): 192 - 201
    02/01/2014 Authors: Stenger EO; Rosborough BR; Mathews LR; Ma H; Mapara MY; Thomson AW; Turnquist HR
  • IL-12(hi) Rapamycin-Conditioned Dendritic Cells Mediate IFN-gamma-Dependent Apoptosis of Alloreactive CD4(+) T Cells and Limit Graft-Versus-Host Diseas
    Volume: 120
    11/16/2012 Authors: Stenger EO; Rosborough BR; Mathews L; Ma H; Mapara M; Thomson AW; Turnquist HR
  • Dendritic cells and regulation of graft-versus-host disease and graft-versus-leukemia activity.
    Blood Volume: 119 Page(s): 5088 - 5103
    05/31/2012 Authors: Stenger EO; Turnquist HR; Mapara MY; Thomson AW
  • Apoptosis of Alloreactive CD4+T Cells by Immunomodulatory IL-12hi Rapamycin-Conditioned Dendritic Cells Is IFN-gamma-Dependent
    Volume: 12 Page(s): 110 - 110
    05/01/2012 Authors: Stenger EO; Rosborough BR; Mathews LR; Ma H; Mapara MY; Thomson AW; Turnquist HR
  • IL-12(hi) RAPAMYCIN-CONDITIONED DENDRITIC CELLS INDUCE APOPTOSIS OF ALLOREACTIVE CD4(+) T CELLS IN AN IFN-gamma-DEPENDENT MANNER AND INHIBIT GRAFT-VERSUS-HOST DISEASE
    Volume: 18 Page(s): S361 - S361
    02/01/2012 Authors: Stenger EO; Rosborough BR; Mathews LR; Ma H; Mapara MY; Thomson AW; Turnquist HR
  • Family-centered multidisciplinary rounds enhance the team approach in pediatrics.
    Pediatrics Volume: 123 Page(s): e603 - e608
    04/01/2009 Authors: Rosen P; Stenger E; Bochkoris M; Hannon MJ; Kwoh CK
Read more publications Fewer publications
Directory
  • Faculty Profiles
Emory University Homepage

Contact & Location

Emory University School of Medicine
100 Woodruff Circle
Atlanta, GA  30322 USA
  • Contact Us
  • Maps & Directions
  • Careers

Information For

  • Alumni
  • Faculty & Staff
  • Patients
  • Residents & Fellows
  • Students
Support the School of Medicine School of Medicine Intranet
facebook facebook twitter twitter linkedin linkedin instagram instagram youtube youtube
© 2025 Emory University
  • Privacy Policy
  • Emergency Information
  • EEO Employer-Disability/Veteran Statements